Shenzhen Children's Hospital

Shenzhen Children's Hospital does not currently operate a dedicated English-language International Patient Department, and its official website is published primarily in Chinese. This means that international families generally cannot navigate the appointment, admission and treatment process directly without significant external coordination. CancerFax fills this gap as your single Mandarin-speaking coordinator throughout the entire journey. You begin by sharing your child's complete medical records, including pathology and bone marrow biopsy and aspirate findings, flow cytometry, cytogenetics, recent imaging, prior chemotherapy or transplant treatment summaries through our secure intake. Our clinical team reviews the case, identifies whether Shenzhen Children's Hospital is genuinely the right fit for the specific pediatric diagnosis, and where useful compares it with other top Chinese pediatric haematology and oncology pathways such as the Institute of Hematology and Blood Diseases Hospital in Tianjin, Beijing Children's Hospital or Lu Daopei Hospital for haematology cases.

Once a clinical plan is confirmed, CancerFax prepares your full pre-travel pack: the hospital's official cost estimate translated into English (shared with you without any CancerFax mark-up), Chinese visa documentation, accredited translation of your home-country reports into Chinese, in-person interpreter support during consultations and ward rounds, accommodation guidance in central Shenzhen (Futian) or Longhua District near the respective campuses, and travel logistics via Hong Kong, Shenzhen Bao'an or Guangzhou airports. We remain your single point of contact through admission, BMT or chemotherapy treatment, discharge and post-treatment follow-up. There is no fee to the family for any of this coordination.

Shenzhen Children's Hospital is the only Grade 3A (Tertiary Grade A) pediatric specialty hospital in Guangdong Province. Its strongest internationally relevant area is pediatric haematology and oncology: the Department of Pediatric Hematology and Oncology has ranked #1 among children's hospitals in Guangdong Province for five consecutive years and #4 nationally among all Chinese children's hospitals on the Annual Technological Influence Ranking List of Hematology Departments published by the Institute of Medical Information of the Chinese Academy of Medical Sciences. The hospital actively treats childhood acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), pediatric lymphoma, severe beta-thalassaemia (a particularly important indication given the higher prevalence of beta-thalassaemia in southern China and across Southeast Asia), aplastic anaemia, inherited haematological disorders and pediatric rare diseases. The wider hospital has provincial-level strength in pediatric surgery, pediatric intensive care medicine, neonatology, pediatric pulmonary medicine, pediatric rheumatology and immunology, and integrated TCM-Western pediatric medicine.

Yes, the hospital operates an active pediatric bone marrow transplantation programme for childhood leukaemias, lymphomas, severe thalassaemia, aplastic anaemia and inherited haematological disorders. The hospital marked 2026 World Thalassemia Day with a dedicated programme specifically highlighting BMT as a curative pathway for transfusion-dependent beta-thalassaemia patients, reflecting genuine clinical activity in this area. Pediatric BMT capacity, including the number of HEPA-filtered or laminar flow isolation rooms and annual transplant volumes, should be confirmed through CancerFax with the hospital before any travel commitment. For pediatric CAR T-cell therapy specifically, the hospital is a national drug clinical trial institution with multiple professional teams including pediatric haematology and oncology, but the specific commercial CAR-T products, investigational protocols and patient eligibility criteria available at Shenzhen Children's Hospital should also be confirmed before travel. For families specifically seeking the highest-volume pediatric and adult CAR-T experience in China, CancerFax may discuss parallel options including Lu Daopei Hospital in Beijing-Yanda alongside the Shenzhen Children's Hospital pathway.

As of January 2026, Shenzhen Children's Hospital has publicly announced that it is in the process of pursuing international hospital accreditation (commonly understood to be JCI, the Joint Commission International gold seal), but this accreditation has not yet been formally achieved. This means that international families considering Shenzhen Children's Hospital today should be aware that the hospital is operating to Chinese Grade 3A standards (the highest level of the Chinese hospital classification system, equivalent in many ways but not directly comparable to international JCI standards), and is actively working toward JCI accreditation but has not yet completed the process. CancerFax provides full transparency on this status and will update you on accreditation progress as the hospital advances through the JCI review. For families who specifically require care at a currently JCI-accredited Chinese pediatric institution, alternative options including Shanghai Jiahui International Hospital (JCI-accredited) may be discussed, though Jiahui does not have the same depth of pediatric haematology and oncology specialty experience as Shenzhen Children's Hospital.

As a Chinese public Grade 3A pediatric hospital under the Shenzhen Municipal Health Commission, Shenzhen Children's Hospital offers paediatric cancer and BMT treatment at significantly lower cost than equivalent care at private international hospitals or at academic pediatric cancer centres in the United States, the United Kingdom, Singapore or other high-cost healthcare markets. Pediatric allogeneic bone marrow transplantation, for example, is typically 50 to 70 per cent less expensive than the equivalent procedure in Western hospitals, and pediatric chemotherapy protocols are dramatically less expensive than equivalent care in the US. Treatment costs at Shenzhen Children's Hospital are broadly comparable with other top Chinese public pediatric hospitals and meaningfully lower than private international pediatric hospitals in China. CancerFax shares the hospital's official cost estimates with you at no extra charge and without any CancerFax mark-up, and we are happy to compare them openly with other Chinese, Indian, Korean, Singaporean and Western pediatric cancer hospital alternatives before any decision is made. We always recommend asking for a 'complication contingency' estimate alongside the base treatment cost, particularly for pediatric BMT cases where infection or chronic GVHD complications can add meaningfully to the total.